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Abstract
Background: More and more antiretroviral therapies are being developed for treatment of HIV infection. The in-
vivo efficacy of these drugs is commonly predicted based on in-vitro measures of antiviral effect. One primary in-
vitro measure is the IC50, the amount of drug required for 50% inhibition of viral replication. We have previously
shown that HIV life-cycle kinetics impact clinically observed HIV viral dynamics. Here we present a mathematical
model of how they affect the pharmacodynamics of antiretroviral drugs.
Results: We find that experimentally measured antiretroviral IC50s are determined by three factors: (i) intrinsic drug
properties (e.g. drug-target binding), (ii) kinetics of the HIV life cycle, and (iii) kinetics of drug-inhibited infected
cells. Our model predicts that the IC50 is a declining function of the duration of the drug-susceptible stage in the
host cell. We combine our model with known viral life-cycle kinetics to derive a measure of intrinsic properties,
reflecting drug action, for known antiretroviral drugs from previously measured IC50s. We show that this measure
of intrinsic drug property correlates very well with in vitro-measured antiviral activity, whereas experimentally
measured IC50 does not.
Conclusions: Our results have implications for understanding pharmacodynamics of and improving activity of
antiretroviral drugs. Our findings predict that drug activity can be improved through co-administration of
synergistic drugs that delay the viral life cycle but are not inhibitory by themselves. Moreover, our results may
easily extend to treatment of other pathogens.
This article was reviewed by Dr. Ruy Ribeiro, Dr. Ha Youn Lee, Dr. Alan Perelson and Dr. Christoph Adami.
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Background
In the last twenty-five years, dramatic improvements
have been made in highly active antiretroviral therapy
(HAART) against the human immunodeficiency virus
(HIV) [1-3]. As more effective and novel classes of anti-
retroviral therapies are developed, it becomes increas-
ingly important to understand the mechanism of action
for these medications.
Two pharmacodynamic properties primarily determine
the activity of a drug: the IC50, i.e., the concentration of
drug required for 50% inhibition, and the sigmoidicity of
the concentration-response curve, as determined by a
Hill coefficient. Using a novel in vitro drug assay [4], a
recent study reported pharmacodynamic parameters of
IC50 and Hill coefficient for over 25 antiretroviral drugs
within the nucleoside-analogue reverse transcriptase
inhibitors (nRTIs), non-nucleoside-analogue reverse
transcriptase inhibitors (nnRTIs), protease inhibitors
(PIs), integrase inhibitors (INIs), and fusion inhibitors
(FIs) [5]. This work revealed drug-class-specific pharma-
codynamic properties. Certain drug classes may be more
efficacious than others by virtue of greater sigmoidicity
of the concentration-response curve–with some protease
inhibitors alone exhibiting greater than nine logs sup-
pression of viral replication [5] in CD4+ T cells. While
there is now a preponderance of data describing the
activity of different antiretroviral drugs, the impact of
viral life cycle kinetics on antiviral pharmacodynamics
remains unclear.
We and others have previously observed that the
kinetics of the viral life cycle may quantitatively impact
viral dynamics in response to treatment [6-8,8]. Here we
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ence the pharmacodynamics of antiretroviral drugs,
using a general and simple mechanistic mathematical
model of HIV antiretroviral pharmacodynamics. We
find that classical measures of potency such as the IC50
may be functions of viral life-cycle kinetics. We explore
how pharmacodynamics would be expected to vary
between different virus-producing cell types and how
viral life-cycle kinetics may be manipulated to improve
drug efficacy. Finally, we use our model to extract infor-
mation about properties of known antiretroviral drugs.
IC50 tends to be a poor reflection of antiviral activity
when comparing antiviral activity across drug classes
such because the IC50 of antiretroviral drugs correlates
poorly with suppression of viral replication at physiolo-
gic drug concentrations [5]. We use our model to elimi-
nate the confounding effects of viral life-cycle kinetics
from IC50, deriving a measure of intrinsic drug activity
that correlates strongly with antiviral activity as mea-
sured by the instantaneous inhibitory potential in a sin-
gle round cell-culture assay system. Our findings offer
novel mechanistic insight into the efficacy of antiviral
drugs and suggest novel approaches for maximizing the
efficacy of HAART.
Methods
A mathematical model of antiretroviral drug action
The pharmacologic effect of an antiretroviral drug on
viral replication in in-vitro assays has been described
with non-linear sigmoidal models, such as the Median-
Effect model by Chou and Talalay [9]. This model states
that funaffected, the fraction of HIV-infected cells that are
uninhibited and proceed through the viral life cycle, is
given by
funaffected =
1
1+

[c]
IC50
m,
(1)
where [c] is the concentration of drug, IC50 is the
concentration of drug that produces a 50% reduction in
maximal viral replication, and m is a Hill coefficient that
determines the sigmoidicity of the concentration-
response curve and may reflect cooperativity at the level
of molecular binding. While such non-linear sigmoidal
models can offer insights into antiretroviral activity, e.g.
through fitting of the IC50 or the Hill coefficient m to
concentration-response data, they cannot give mechanis-
tic insight because HIV viral dynamics do not meet
important assumptions underlying these models [10]. In
any situation, if biology obviously violates model
assumptions, then the model cannot be trusted to gen-
erate accurate predictions, even if it fits available data.
Specifically, HIV viral dynamics do not meet the
assumptions of (i) free diffusion of drug and the sub-
strate (HIV enzymes are spatially restricted to the virion
or infected cell and therefore an antiretroviral drug
molecule may only act on HIV enzymes in the same vir-
ion or infected cell) and (ii) enzyme recycling (once a
single reverse transcriptase molecule acts in an infected
cell, it cannot go to another infected cell to act).
T os t u d yh o wt h es t a g ea tw h i c had r u ga c t sm a y
affect pharmacodynamics we present a general and sim-
ple mechanistic mathematical model of HIV kinetics
that can be applied to any class of antiretroviral drug or
any virus-producing cell type in the setting of pharma-
cologic inhibition (Figure 1). This model is constructed
to reflect the in-vitro experiments that are used to
quantify antiretroviral pharmacodynamic parameters
such as IC50. Our model is defined by three variables
corresponding to different stages of the viral life cycle
within infected cells (e.g. reverse transcription, integra-
tion, maturation): xpre represents the stage that is sus-
ceptible to the drug effects; xpost represents the stages
not susceptible to the drug; these stages will produce
virus; xI represents stages that are being actively inhib-
ited by the drug. For example, if applying this model to
studying reverse transcriptase inhibitors, xpre would
represent infected cells undergoing reverse transcription,
which would be susceptible to reverse transcriptase inhi-
bitors, xpost would represent infected cells that have pro-
gressed beyond reverse transcription, and xI would
Gpre
GI
xpre xpost
xI
kdrug[c] k-I
kHIV
Figure 1 Schematic of the model. An HIV-infected cell type (xpre)
that is susceptible to an antiretroviral targeting the step in the viral
life cycle that proceeds at rate kHIV after which the infected cell is
no longer susceptible to the antiretroviral drug (xpost). The drug-
susceptible cell can be inhibited at rate kI to become an inhibited
cell (xI), which can progress no further in the HIV viral life cycle. This
inhibition may be reversed at a rate k-I. Cell types xpre and xI decay
(e.g. through death of the cell or decay of the offending HIV virion)
at rates δpre and δI, respectively.
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by a reverse transcriptase inhibitor.
This model is defined by the system of ordinary differ-
ential equations:
dxpre
dt
= k -IxI −

kI + δpre + kHIV

xpre, (2)
dxpost
dt
= kHIVxpre, (3)
dxI
dt
= kIxpre − (k -I+ δI)xI. (4)
Here, kHIV is the rate at which the drug-susceptible
state transitions to a non-susceptible state. In our exam-
ple of reverse-transcriptase inhibitors, kHIV would be the
rate of reverse transcription. kI is the rate at which viral
replication in susceptible cells (xpre)i si n h i b i t e d ;k-I is
t h er a t ea tw h i c ht h ei n h i b i t ion of susceptible stages
decays. The parameters δpre and δI represent the decay
rates for susceptible and inhibited cell stages. Cell death
is ignored in the xpost state because it is unlikely to play
a major role under the experimental protocol used to
generate published data [5]. Following classic enzyme
kinetics and the law of mass action, the rate kI is a func-
tion of the drug’s interaction with the target cell. The
interaction of a drug with the target cell includes
uptake, intracellular transport, drug binding to its target
(designated kdrug), and the drug concentration [c], and is
given by kI = kdrug [c]
m. The parameter m determines
the sigmoidicity of the concentration-response curve. As
yet, the mechanism underlying the value of m is
unknown and its value is empirically determined
through fitting of experimental data to a concentration-
response curve. We will consider kI t ob eac o n s t a n t
because kdrug is a constant and drug concentration is
approximately constant in short term drug assays where
pharmacodynamic experiments are performed.
For model simulations and calculations, we made
parameter choices based on published results for the
kinetics of HIV infected CD4+ T cells [11] and the
kinetics of the different drug classes in CD4+ T cells
[12-17].
Results
Intrinsic and extrinsic factors affect pharmacodynamics
A concentration-response curve for any given enzyme
inhibitor (e.g. a drug) is the plot of enzyme activity in
the presence of inhibitor against inhibitor concentration.
In the case of antiretroviral drugs, enzyme activity is
indirectly measured in assays as the fraction of infected
target cells that proceed through the HIV viral life cycle
compared to the number of such cells in the absence of
the drug. In our model, we can calculate the fraction
funaffected of uninhibited viral replication given a specific
drug concentration by taking the asymptotic ratio of
xpost in the presence and the absence of the drug. Thus,
we have funaffected =[ xpost(∞)]kI =0/[xpost(∞)]kI=0.F o r
our model, we obtain:
funaffected =
1
1+
δIkdrug[c]
m
(δpre + kHIV)(k -I+ δI)
.
(5)
Equation 5 is in the same form as the Median-Effect
model (equation 1) where the Hill coefficient is similarly
equal to m (and may reflect the order of the reaction or
molecular level cooperativity). By definition, the IC50
corresponds to the drug concentration [c]at which funaf-
fected = 1/2. We find
IC50 =

(δpre + kHIV)(k -I+ δI)
δIkdrug
1/m
. (6)
Thus, our model links fundamental constants that
describe how a drug acts to the experimentally observa-
ble IC50. Equation 6 suggests that three factors play a
role in determining the IC50 of a drug: intrinsic proper-
ties of the drug, the kinetics of the viral life cycle, and
the kinetics of inhibited infected cells. The intrinsic
properties of a drug (kdrug) include how well it is taken
up, complexes with, and inhibits its target, and how
easily the reverse process takes place (k-I). When a drug
accesses its target better (larger kdrug), the IC50 is lower.
The stage of the viral life cycle at which the drug acts
impacts the IC50 as well. As a general rule, the longer
the drug-susceptible state exists (lower rates of decay
δpre or transition to the non-susceptible state kHIV), the
lower the IC50, because there is more time for the drug
to act and affect target cells. Finally, the faster the inhib-
i t e dv i r u si sd e p l e t e d( h i g h e rδI), the lower the IC50
because more susceptible cells are depleted before the
drug dissociates and a transition to the non-susceptible
state is possible. However, as the off-rate of the drug (k-
I) decreases (i.e. there is less dissociation of the drug),
the decay rate of inhibited virus, δI, has less of an
impact on the IC50.
Cell-type specific kinetic properties of antiviral drugs may
be related to viral life-cycle kinetics
While the IC50 of a drug is dependent on parameters
related to the stage in the viral life cycle targeted by the
drug (δpre, kHIV, δI), these parameters may also depend
on the virus-producing cell type. Therefore, IC50 may
vary with the type of host cell. To date, four primary
cell types are known to support HIV replication to var-
ious degrees [18,19]: (i) activated CD4+ T cells, (ii)
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cytes. Activated CD4+ T cells and macrophages are the
primary HIV-producing cell types and support all stages
of the viral life cycle [20]. Kinetics of reverse transcrip-
tion in activated CD4+ T cells are in general more rapid
than in macrophages [18,19,21]. Our model would
therefore predict that IC50s of HIV reverse transcriptase
inhibitors would be lower in macrophages than in acti-
vated CD4+ T cells (see Section 1 of Additional File 1).
Reverse-transcriptase-inhibitor IC50s measured in
macrophages and in CD4+ T cells using comparable
experimental methods are greatly limited in the litera-
ture. We have found that previously reported IC50s of
five RT inhibitors in macrophages are on average 3 fold
lower than IC50s measured using a similar and compar-
able single round infection assay in CD4+ T cells (see
Section 1 of Additional File 1 and Supplemental Figure
1 of Additional File 2). Although this 3-fold difference is
not statistically significant (p = 0.1422), the trend of the
data is in the direction we predict; moreover, with only
five drugs, the statistical power to resolve any existing
difference is low. As analysis of currently available but
sparse data is equivocal, future studies that quantify the
kinetics of reverse transcription in macrophages and
IC50 measurements of more drugs in macrophages will
give better insight into our model predictions.
Two additional sources of viremia that may be of sig-
nificance include pre-integration latently infected resting
CD4+ T cells (PLIC) [22], which produce virions on T
cell activation, and infected monocytes [19], which are
believed to produce virus on cell differentiation into
tissue macrophages. Although there are no published
reports of IC50s for antiretroviral drugs using single-
round infection assays in either PLIC or monocytes, we
may use our model to predict how IC50 may be affected
in these cell types. In both PLIC and monocytes, the
kinetics of reverse transcription are slower than in pro-
ductively infected CD4+ T cells and macrophages,
respectively. Our model would therefore predict that the
IC50 of reverse transcriptase inhibitors should be lower
in PLIC and monocytes (see Section 2 of Additional File
1 and Supplemental Figure 2 in Additional File 3).
In the setting of HAART, HIV viremia decays with a
triphasic decay. The first phase of decay represents
declining virus production of productively infected, acti-
vated CD4+ T cells. The third phase of decay likely
represents slowly decaying, latently infected resting CD4
+ T cells. The identity of the virus-producing cells of
the second phase, however, remains largely unknown.
We have previously constrained the transition rate from
post-reverse transcription to post-integration for the
virus-producing cells of the second-phase decay to be
quite low (with a half-life on the order of 1 week)
[6-8,8]. Of all cell types that are infected by HIV, the
kinetic constraints placed on these cells are most consis-
tent with infected monocytes, where the slow progres-
sion from RT to integration may reflect the long time to
differentiation into macrophages, followed by rapid inte-
gration (occurring in differentiated macrophages). In
such a scenario, we would expect integrase inhibitors to
have the same IC50 in the virus-producing cells of the
second phase as in macrophages. However, it is possible
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Figure 2 Relationship of IIPmin with IC50 and kdrug. log IIPmin plotted against (A) log IC50 (represented by filled circles) or (B) log kdrug
(represented by stars; with kdrug calculated as (δpre+kHIV)/(IC50)
m) for 25 different antiretroviral drugs (listed in Supplemental Table 1 of Additional
File 1 and color-coded by drug class). Line of best fit through the data points in black. IIP and IC50 data from reference [5].
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which integration proceeds slowly and constantly to
meet these kinetic constraints. In this scenario, our
model predicts integrase inhibitors to have a lower IC50
in the virus-producing cells of the second phase than in
macrophages. This predicted difference may help to
identify the virus-producing cells of second-phase
viremia.
Drug-intrinsic determinants may be quantified using
known kinetics of the viral life cycle
Thus far we have predicted that the experimentally
observed IC50 of an antiretroviral drug (ARV) is deter-
mined by the kinetics of the viral life cycle but also by
factors intrinsic to the ARV. In our model the para-
meter kdrug is the amalgam of these ARV-intrinsic fac-
tors and is the rate at which a drug acts on its target,
reflecting not only binding to the target but also intra-
cellular transport, modification, or other direct interac-
tion between the drug and the target cell. Our model
m a ya l s ob eu s e dt oe s t i m a t et h ev a l u eo fkdrug for spe-
cific drugs. From equation 6, it is apparent that for
drugs with low k-I compared to δI,t h eI C 5 0w i l lb e
predominantly determined by the kinetics of the stage
in the viral life cycle at which the drug acts (i.e. δpre
and kHIV)a n db ykdrug. In the case of productively
infected CD4+ T cells and macrophages, experimental
evidence of irreversibly or tightly binding antiretroviral
drugs [23,24] suggests that δI >> k-I. In this case, we
can neglect k-I in (6), δI cancels, and we obtain kdrug ≈
(δpre+kHIV)/(IC50)
m.T h ein vitro IC50s and m-values of
twenty-seven ARVs have been previously reported [5].
Furthermore, the values of δpre and kHIV have been
reported or approximated for many of these drugs (see
Section 3 of Additional File 1) and may therefore be
used to solve for kdrug (see Supplemental Table 1 in
Additional File 1). We find that the values of kdrug
clearly show class-specific trends, with protease inhibi-
tors having the largest kdrug values in general. The
instantaneous inhibitor potential (IIP) is an empirically
derived measure of antiviral drug activity and reflects
the log-fold decrease in viral replication by an ARV at
a specified concentration [5]. IIP, which may be mea-
s u r e da tt h ec l i n i c a lm i n i m u m( I I P min), average (IIPavg),
and maximum (IIPmax) drug concentrations, reflects
the best measurement of antiviral effect [5] in compar-
ison to traditional pharmacodynamic properties, such
as the IC50. When we reanalyzed the data from refer-
ence [5], we found poor correlation between the log
(IC50) of antiretroviral drugs and their IIPs measured
at their respective IIPmin (spearman rank correlation, r
= -0.323, P = 0.136) (Figure 2A), IIPavg (r = -0.365, P
=0 . 0 9 3 ) ,a n dI I P max (r = -0.356, P = 0.101) (see Sup-
plemental Figures 3A and 3C in Additional File 4 for
IIPavg and IIPmax). In contrast, the calculated value of
log(kdrug)c o r r e l a t e dv e r yw e l lw i t hI I P min (r = 0.681, P
= 0.0019) (Figure 2B), IIPavg (r = 0.729, P = 0.0008),
and IIPmax (r = 0.716, P = 0.0010), (see Supplemental
Figures 3B and 3D in Additional File 4 for IIPavg and
IIPmax). At drug concentrations higher than IC50, IIP–
calculated as -log(funaffected)–is roughly equal to mlog
(c)-mlog(IC150). It is therefore approximately a linear
function of both m and log(IC50) if the respective
other quantities are held constant (see Section 4 of
Additional File 1 and Supplemental Figure 4 in Addi-
tional File 5). However, although the correlation
between IIP and log(IC50) is not very strong (Figure
2A, Supplemental Figures 3A and 3C in Additional
File 4), we find that IIP is very strongly correlated with
the value of m (see Section 4 of Additional File 1 and
Supplemental Figure 4 in Additional File 5). It is this
strength of correlation between IIP and m that is the
mathematical foundation for the correlation between
IIP and log(kdrug), which is also linear function of m.I t
is presently unclear why there is a strong correlation
between IIP and m but not between IIP and IC50. One
possible explanation is that the clinical concentrations
at which IIP is measured tend to be chosen in propor-
tion to the IC50. In this case, c/IC50 is going to be
approximately constant and thus will not correlate
with IIP. However, regardless of the reason why IIP
correlates more strongly with m than with IC50, our
results show that a parameter (kdrug)d e s i g n e dap r i o r i
to purely reflect intrinsic drug properties (such as affi-
nity for its target) correlates well with the experimen-
tally measured suppression of viral replication.
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Figure 3 IC50 color-coded as a function of δpre and kHIV.F o ra
drug with m = 1 and kdrug = 100, the parameter regimes generally
occupied by the various stages of the HIV viral life cycle in activated
CD4+ T cells and macrophages (for more details, see Section 5 of
Additional File 1) are outlined with a solid line and parameter
regime potentially available through pharmacologic intervention
approximated with a dashed line based on cell-specific properties.
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the antiretroviral drug to its enzymatic target but also of
drug uptake, retention, and transport, experimental
quantification of any of these factors will provide insight
into the others, given their mathematical relationships
in determining kdrug. For example, when comparing dif-
ferent antiretroviral drugs from the same class, if their
relative kdrug values do not correlate with their relative
rate of binding to the target HIV protein, then one may
glean insight into the relative interaction of the drugs
with the host cell (e.g. uptake, intracellular transport,
modification, degradation, or expulsion).
Antiretroviral activity may be improved through
modifying the kinetics of the viral life cycle
Our results suggest that IC50 and therefore antiviral
activity for a specific drug may be improved through
modifying the kinetics of the viral life-cycle stage that is
targeted by the drug. Such manipulation of viral life-
cycle kinetics could occur through administration of an
additional drug that may not be an efficient inhibitor of
HIV per se but that modifies the viral kinetics in a bene-
ficial manner. For example, decreasing the rate kHIV (e.g.
reverse transcription) will decrease the IC50 of a
reverse-transcriptase inhibitor by giving the inhibitor
more time to act. However, manipulation of viral life-
cycle kinetics is constrained by the physiologic extent to
which these kinetics can be realistically altered in the
different virus-producing cell-types (Figure 3).
In general, drug classes with greater concentration
response sigmoidicity (i.e. a larger Hill coefficient m)
should have better antiviral activity at drug concentra-
tions much higher than their IC50. By contrast, drugs
with lower m may have greater antiviral effect at drug
concentrations far below their IC50s (Figure 4A), if the
antiretroviral with higher m (drug #1 with m1)a l s oh a s
a higher IC50 than the antiretroviral drug with lower
m (drug #2 with m2). This condition can arise for rou-
tinely used antiretroviral drugs such as the protease
inhibitor nelfinavir (m = 1.81, IC50 = 0.1668 μm) and
the nRTI abacavir (m = 0.95 and IC50 = 0.0344 μm).
In these cases, the antiviral activity of the drug with
higher m at concentrations exceeding its IC50 over-
comes the antiviral activity of the drug with lower m
at similar concentrations. The drug concentration at
which the antiviral activity of the drug with higher m
overcomes that of drug with lower m is the value of
[c]a tw h i c ht h et w ofunaffected ([c]) curves for the two
F
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Figure 4 Simulations that demonstrate how altering viral life cycle kinetics can improve drug efficacy. Log-log concentration-response
curves for (A) a hypothetical drug #1 and drug #2 where IC501 > IC502 but m1 = 1 and m2 = 3, showing how decreasing IC50 in drug #1
changes the concentration regime where each drug may have greater antiviral activity, and (B) with the example of how abacavir antiviral
activity (blue concentration-response curve for IC50 = 0.0344 μM, red concentration-response curve for IC50 = 0.0172 μM) relative to nelfinavir
(black concentration-response curve) may be improved by decreasing IC50. Light blue bar above indicates the clinical concentration range of
abacavir and orange bar indicates clinical concentration range of nelfinavir.
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drug) at this point is:
f∗
unaffected =
IC50
[m2
1+m1(m2−m1)]/(m2−m1)
1
IC50
[m2
1+m1(m2−m1)]/(m2−m1)
1 + IC50
m1m2/(m2−m1)
2
(7)
which occurs at a drug concentration of
[c]=

IC50
m2
2 /IC50
m1
1
1/(m2−m1).
If the activity of the antiretroviral drug with low m is
increased through pharmacologic interventions aimed at
the kinetics of the viral life cycle in order to decrease
the IC50 (e.g. through increasing kHIV or δpre) then the
value of f∗
unaffected decreases thereby decreasing the con-
centration range in which drug 2 is superior to drug 1
(Figure 4A). The effect of decreasing IC50 on lowering
this funaffected is best when
IC50
m1m2/(m2−m1)
2 >> IC50
[m2
1+m1(m2−m1)]/m1m2
1 . However,
even for the general case of a protease inhibitor like nel-
finavir with m = 1.81 and IC50 = 0.1668 μM in compar-
ison to an nRTI like abacavir with m = 0.95 and IC50 =
0.0344 μm, f∗
unaffected can be reduced by 75% if the IC50
of abacavir is reduced by half (Figure 4B).
Discussion
Continued progress in treatment of HIV infection
depends not only on development of new antiretroviral
drugs but also on complete understanding of how these
drugs act. Such insight will allow for pharmacologic
interventions that can further improve the action of
known antiretroviral drugs. Recent experimental
advances, such as the development of direct single
round infection assays [4,25] that do not suffer from the
unreliability of indirect or multiround assays [26,27]
have provided a better understanding of the pharmaco-
dynamic properties for available antiretroviral drugs.
Moreover, class-specific pharmacodynamics properties
that impact pharmacologic effect are now apparent as
well. These properties reflected in pharmacodynamic
parameters are obtained through the empirical fitting of
models, such as the Michaelis-Menten or Median-Effect
models of enzyme kinetics, to experimental data [10].
W h i l et h e s em o d e l sc a no f f e ra ne m p i r i c a lb a s i sf o r
understanding the pharmacodynamics and activity of
antiretroviral therapy, they cannot provide mechanistic
insight because HIV viral kinetics do not meet many of
the important assumptions that underlie these models.
Here we present a simple and general mechanistic
model of HIV interaction with antiretroviral drugs that
takes into account the kinetics of the HIV viral life
cycle. We have recently argued that the phase of the
viral life cycle where a drug acts may have important
implications for clinically observed viral dynamics [7].
Experiments in vitro have confirmed our argument [6].
Here, we demonstrate that the kinetics of the viral life
cycle may also impact the pharmacodynamic properties
of antiretroviral drugs. More broadly, we show that the
IC50 of a drug is impacted by three categories of fac-
tors: (i) drug-intrinsic properties related to binding of
drug to target, (ii) the kinetics of the stage of the viral
life cycle at which the drug acts, and (iii) the kinetics of
an infected cell that has been effectively inhibited. The
theoretical framework provided by our model can be
useful for gaining insight into either drug-intrinsic or
-extrinsic factors when information about the other is
available. Moreover, we have used the mathematical
relationship between these factors that determine drug
IC50 to quantify the drug-intrinsic properties (such as
the strength and rate of interaction between an antire-
troviral drug and its target) reflected by our model para-
meter kdrug for 22 different antiretroviral drugs. Unlike
experimentally measured IC50, we find that kdrug corre-
lates very well with experimentally measured antiviral
activity for these drugs, as reflected by IIP.T h em a t h e -
matical underpinning of this correlation lays in the
strong correlation we demonstrate between IIP and the
parameter m. However, future experiments, which
empirically fit the approximate value of kdrug to dose-
response data using the relationship funaffected =1 / [ 1
+kdrugc
m/(δpre+kHIV)] (based on the relationship between
kdrug and IC50) will allow correlation between an inde-
pendently obtained value of kdrug and IIP.
The quantitative predictions of our model depend on
accurate experimental measurements of model para-
meters for the different stages of the viral life cycle and
in the different virus-producing cell types, which will
also require experimental characterization of the drug-
susceptible state. Furthermore, our model predictions
may be confounded by other factors such as drug-speci-
fic interactions between other HIV machinery (e.g. exci-
sion machinery) or cellular machinery such as
APOBEC3G as well as expression/activity level of MDR/
P-glycoprotein pumps that may depend on drug concen-
tration or be specific to the type of the host cell. Future
experiments in this area will give greater insight into the
magnitude of effect that such factors have on our model
predictions.
The clinical efficacy of an antitretroviral drug is
dependent on many factors such as the background
regimen, adherence, resistance barrier, pharmacoki-
netics, and pharmacodynamics. While all of these factors
represent avenues for improvement of currently existing
drugs and development of new drugs, pharmacologic
approaches to optimizing drug pharmacodynamics may
allow for greater (1) flexibility in successful background
regimens, (2) forgiveness in patient noncompliance, (3)
protection from development of drug resistance in the
cases of low resistance barriers and (4) antiviral activity
Sedaghat and Wilke Biology Direct 2011, 6:42
http://www.biology-direct.com/content/6/1/42
Page 7 of 10given specific pharmacokinetic properties. Our results
have important therapeutic implications, suggesting an
approach to enhancing antiretroviral activity through
pharmacologic interventions that may prolong the drug-
susceptible state and opening the potential for drugs
that may boost efficacy of antiretroviral drugs through
modification of viral life-cycle kinetics. This prediction
of our model may be tested experimentally through
measurement of antiretroviral-drug IC50s in viruses car-
rying mutations specifically aimed at altering the drug-
targeted stages of the viral life cycle (e.g. a mutation
that slows the rate of reverse transcription). This effect
may have already been clinically observed when hydro-
xyurea, which slows the process of reverse transcription
by depleting the intracellular pools of dATP, was
reported to enhance the activity of the reverse transcrip-
tase inhibitor ddI, which specifically acts at the point of
dATP insertion into the viral DNA [28]. If the func-
tional effect of hydroxyurea is to slow the process of
reverse transcription, our model predicts that the
increased activity of ddI in the presence of hydroxyurea
is due to a lower IC50. Moreover, our findings suggest
that slowing the viral life cycle through pharmacologic
interventions may serve as a means for at least partially
overcoming drug resistance mutations that can increase
the drug’s IC50 [29].
Our results also have implications for the design of
HAART regimens. Drugs acting within the same period
of the viral life cycle but using different mechanisms of
action may be used to combat resistance mutations.
Resistance mutations often come at a fitness cost, for
example through slowing HIV enzyme kinetics. Our
model predicts that a mutation causing resistance to one
drug may increase efficiency of the second drug. For
example, consider resistance to one of two drugs acting
at the same stage of the viral life cycle, e.g., a protease
inhibitor and a maturation inhibitor. The mutation con-
ferring resistance may slow the rate of progression for
that stage of the viral life cycle (under the assumption
that the wild-type virus is optimized to complete each
stage of the viral life cycle as efficiently as possible). Our
model predicts then that the antiviral activity of the other
drug would increase due to a decreased IC50 resulting
from slower kinetics. Such an effect has been observed
for the combined use of protease and maturation inhibi-
tors [30]. In the same vein, our results also suggest a
mechanism that may be investigated for experimentally
observed synergism or antagonism between antiretroviral
drugs [31-33]. Furthermore, our model also predicts that
IC50 and therefore antiviral activity may vary between
different virus-producing cell types. After initiation of
HAART, the dominant virus-producing cell changes
through the three phases of viral decay (productively
infected CD4+ T cells during the first phase; most likely
monocyte/macrophages and latently infected CD4+ T
cells during the second and third phases of decay, respec-
tively). Our results suggest the optimization of a HAART
regimen may ultimately require careful consideration of
the prevalence of the different virus-producing cells both
in the short term and the long term.
Conclusions
Overall, our results suggest that consideration for the
kinetics of the viral life cycle may offer substantial
insight into the treatment of HIV. We find that kdrug
and m correlate well with antiviral activity, whereas
IC50 does not. This finding suggests that IC50 may be
confounded by kinetics of the viral life cycle. Moreover,
our results predict not only underlying mechanisms that
determine clinically observed pharmacologic properties
of antiretroviral drugs but also suggest approaches for
development of antiretrovirals including a novel
approach for overcoming resistance through pharmaco-
logic agents that affect the kinetics of the viral life cycle.
Finally, our model and results will apply with minor
changes to many other pathogens.
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Reviewers Comments
Reviewer 1-Dr. Ruy Ribeiro
I appreciate the authors’ thoughtful replies and I believe
that the manuscript is substantially improved and
affords better reading. I think that the main result of the
manuscript namely “a simple and general mechanistic
model of HIV interaction with antiretroviral drugs that
that takes into account the kinetics of the HIV viral life
cycle” is very interesting and a valuable contribution.
We would like to thank Dr. Ribeiro for the overall
positive evaluation of our manuscript.
On the other hand, I still don’t understand much of
the discussion around IC50. Equation (6) that “links
fundamental constants that describe how a drug acts to
the experimentally observable IC50” is very nice. But the
fact that IC50 by itself, without knowing the drug con-
centration, does not describe antiviral efficacy is not sur-
prising. (In my previous comment I meant that IC50 “is
the same as antiviral activity” at that concentration.)
And the fact that IC50 is not a good way to compare
activity across drug classes at different concentrations is
again not surprising, and I am not sure it needs an
explanation.
We agree that none of these facts are terribly surpris-
ing. Yet the way in which IC50 is commonly used in the
literature often is at odds with these facts. Therefore, we
think it is worth pointing them out.
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Page 8 of 10Ia l s od o n ’t agree with the explanation given for the
statement “-log(f) is therefore a linear function of both
ma n dI C 5 0 ”. A linear relationship implies that if the
independent variable (say m, here) doubles and the
dependent variable (say IIP) changes by a factor q; then
when the independent variable quadruples the depen-
dent variable changes by a factor 2q. This is not the
case for the formula presented unless c/IC50 is approxi-
mately constant. There may still be some correlation (as
in y and x in y = x^2), and you may be able to calculate
a correlation coefficient. But the relationship is not lin-
ear for all values (although it may look linear for a cer-
tain range of the variables).
We are not sure whether Dr. Ribeiro’s objection is
that IIP = mlog(c)-mlog(IC50) is only approximately
correct, in the limit of large c, or whether the objec-
tion is that the expression IIP = mlog(c)-mlog(IC50)
does not imply that IIP is a linear function of m and
IC50. We now write “approximately a linear function”
to address the first possibility. In our mind, the expres-
sion IIP = mlog(c)-mlog(IC50)implies a linear relation-
ship of IIP with m and log(IC50), since IIP changes
linearly with either quantity if all other variables are
held constant. To address the second possibility, we
have added “if the respective other quantities are held
constant.”
Reviewer 2-Dr. Ha Youn Lee
As the clarity of the manuscript is significantly
improved, now I have three main comments.
First, we may understand the results of Figure 2A and
Supplementary Figure 4 by assuming that cmin (the clini-
cal minimum concentration) is proportional to IC50.
Since IIPmin is approximately given by m log(cmin/IC50),
we observe a strong correlation between IIPmin and m
as in Supplementary Figure 4 and a poor correlation
between IIPmin and IC50 as in Figure 2A, if cmin and
IC50 are happen to have a linear relationship within 25
antiretroviral drugs which are analyzed here.
We thank the reviewer for making this point and have
added a few sentences at the appropriate location in the
results.
Second, we might interpret the outcome of Figure 2B
from the following relationship:
IIPmin = log(kdrug)-log(δpre + kHIV)+m log(cmin).
According to the supplementary Table I, the values of
kdrug are greater than those of δpre + kHIV by several
orders of magnitude. If m log(cmin) is smaller than log
(kdrug)f o rm o s to ft h e2 5d r u g s ,w es h o u l db ea b l et o
observe a linear relationship between log(kdrug)a n dI I P -
min as log(kdrug) is a leading order term.
It is true that IIP ≈ log(kdrug)-log(δpre+kHIV)+mlog(c)i f
one makes the assumptions that 1) c/IC50 > > 1 and 2)
δI >> k-I. In the case of IIPmin, the assumption that cmin/
IC150 > > 1 does not universally hold true. However the
expression IIPmax ≈ log(kdrug)-log(δpre+kHIV)+mlog(cmax)
would provide one mathematical explanation for why
IIPmax correlates with cmax.
Third, I would like to encourage authors to revise
both abstract and author summary by i) defining IIP
and ii) adding more description about “the measure of
intrinsic drug property”.
i) Neither abstract nor author summary contain the
term IIP. We prefer to leave this term out of both
abstract and author summary because we believe that
these pieces of text should contain as little jargon as
possible.
ii) We have added the following sentence to the
author summary: “We derive a measure of intrinsic drug
properties that captures how well the drug is taken up,
complexes with, and inhibits its target.” We have left
the abstract unchanged, since there already is an expla-
nation of intrinsic drug properties in the abstract:
“intrinsic drug properties (e.g. drug-target binding)”
Reviewer 3-Dr. Alan Perelson
The revised manuscript is acceptable for publication. All
of the concerns I raised in my previous review have
been addressed.
We are glad to hear that Dr. Perelson considers our
manuscript publication-ready.
Reviewer 4-Dr. Christoph Adami
I am happy with the author’s changes to the manuscript.
We are glad to hear that Dr. Adami considers our
manuscript publication-ready.
Additional material
Additional file 1: Supplemental Text. Contains supplemental text and
supplemental Table 1, all of which support results presented within the
manuscript.
Additional file 2: Supplemental Figure 1: Experimentally reported
IC50s for AZT, d4T, ddI, 3TC and TDF. In CD4+ T cells [10] and
macrophages [9].
Additional file 3: Supplemental Figure 2: Log-log dose response
curve for the reverse transcriptase inhibitor 3TC in different cell
types. For 3TC m = 1.15 and simulations are for infection in (A) activated
CD4+ T cells (blue) (where kHIV = 8.32 day
-1, δpre = 0.3466 day
-1 and δI =
0.3466 day
-1) in contrast to PLIC (black) (where kHIV = 0.3466 day
-1, δpre =
0.231 day
-1 and δI = 0.231 day
-1); and (B) in macrophages (red) (where
kHIV = 4.16 day
-1, δpre = 0.0495 day
-1 and δI = 0.0495 day
-1) in contrast to
monocytes (black) (where kHIV = 0.231 day
-1, δpre = 0.0495 day
-1 and δI =
0.0495 day
-1).
Additional file 4: Supplemental Figure 3: Relationship of IIPavg and
IIPmax with IC50 and kdrug. log IIPavg plotted against (A) log IC50
(represented by filled circles) or (B) log kdrug (represented by stars) for 25
different antiretroviral drugs (listed in Supplemental Table 1 of Additional
File 1 and color-coded by drug class). log IIPmax plotted against (C) log
IC50 (represented by filled circles) or (D) log kdrug (represented by stars).
Line of best fit through data points in black. IIP and IC50 data from
reference [10].
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Page 9 of 10Additional file 5: Supplemental Figure 4: IIPs plotted against m.
IIPmin (A), IIPavg (B) and IIPmax (C) plotted against m for 25 different
antiretroviral drugs listed in Supplemental Table 1 of Additional File 1.
Line of best fit through data points in black. IIP and m data from
reference [10].
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